Two studies point to a new way to a vaccinate against drug-resistant Staphylococcus aureus -- also known as MRSA -- the leading US cause of skin, soft tissue, bloodstream and lung infections, as well as deaths from infectious disease. One counteracts the bacteria's tools for evading the immune system; the other disrupts the germ's tissue-damaging mechanism. Each approach reduced the microbe's virulence in mice. The combination may protect people from MRSA and provide lasting immunity.